The MRC Blood Transfusion Committee was disbanded in July 1982 on the basis that its work was being duplicated elsewhere. Read more about The MRC Blood Transfusion Committee was disbanded in July 1982 on the basis that its work was being duplicated elsewhere.
Report on Post-transfusion hepatitis in a London hospital: results of a two-year prospective study was published. The report explained that "It was arbitrarily decided that where such other potential causes existed, the patient would not be regarded as suffering from viral hepatitis." It also acknowledged that the "exclusion of all patients having other possible causes for their liver damage may have contributed to the low incidence of hepatitis in the present study". Read more about Report on Post-transfusion hepatitis in a London hospital: results of a two-year prospective study was published. The report explained that "It was arbitrarily decided that where such other potential causes existed, the patient would not be regarded as suffering from viral hepatitis." It also acknowledged that the "exclusion of all patients having other possible causes for their liver damage may have contributed to the low incidence of hepatitis in the present study".
Dr Brian McClelland reported to the SNBTS directors that he had prepared a protocol for a study of the transmission of NANBH by transfusion for an MRC meeting. Directors agreed at the meeting that they would not proceed with liver function tests on existing donations for the time being. Read more about Dr Brian McClelland reported to the SNBTS directors that he had prepared a protocol for a study of the transmission of NANBH by transfusion for an MRC meeting. Directors agreed at the meeting that they would not proceed with liver function tests on existing donations for the time being.
Dr Paul Holland acknowledged that ALT screening of donors appeared to be a "promising way to decrease the risk of post-transfusion hepatitis", and questioned whether the expected benefit to patients was "worth the drawbacks, especially to the donors and to the blood-service complex". Read more about Dr Paul Holland acknowledged that ALT screening of donors appeared to be a "promising way to decrease the risk of post-transfusion hepatitis", and questioned whether the expected benefit to patients was "worth the drawbacks, especially to the donors and to the blood-service complex".
The Blood Transfusion Research Committee concluded that "The identification of donors and units of blood associated with possible cases of non-A, non-B hepatitis" and "Epidemiological surveys to assess the size of the problem in relation to blood transfusions" required investigation. Read more about The Blood Transfusion Research Committee concluded that "The identification of donors and units of blood associated with possible cases of non-A, non-B hepatitis" and "Epidemiological surveys to assess the size of the problem in relation to blood transfusions" required investigation.
"The Advisory Group on testing of the presence of Hepatitis B surface antigen and its antibody agreed that no new policy on testing for transaminases needed to be adopted. These tests should not be used to screen blood donors." Read more about "The Advisory Group on testing of the presence of Hepatitis B surface antigen and its antibody agreed that no new policy on testing for transaminases needed to be adopted. These tests should not be used to screen blood donors."
Dr Cleghorn reported that several people had "raised transaminases not associated with viral hepatitis. Some 3% of new donors would be excluded if the criterion of one raised transaminase was applied. In addition there would be a problem of responsibility to apparently healthy donors found to have raised transaminase(s)." Read more about Dr Cleghorn reported that several people had "raised transaminases not associated with viral hepatitis. Some 3% of new donors would be excluded if the criterion of one raised transaminase was applied. In addition there would be a problem of responsibility to apparently healthy donors found to have raised transaminase(s)."
The Advisory Group on testing of the presence of Hepatitis B surface antigen and its antibody's terms of reference included "To advise the Department on measures which should be introduced to offer greater safety to recipients of blood and blood products and to protect the interests of blood donors." Read more about The Advisory Group on testing of the presence of Hepatitis B surface antigen and its antibody's terms of reference included "To advise the Department on measures which should be introduced to offer greater safety to recipients of blood and blood products and to protect the interests of blood donors."
The Advisory Group on testing of the presence of Hepatitis B surface antigen and its antibody was opposed to the "routine determination of transaminase levels" but considered further investigation to be warranted and deferred further discussions to its next meeting when Dr Cleghorn would be in attendance. Read more about The Advisory Group on testing of the presence of Hepatitis B surface antigen and its antibody was opposed to the "routine determination of transaminase levels" but considered further investigation to be warranted and deferred further discussions to its next meeting when Dr Cleghorn would be in attendance.
In an article in The British Medical Journal titled, "Post-transfusion non-A, non-B hepatitis in the Netherlands", the significance of NANBH and the need for a test for it was outlined. Read more about In an article in The British Medical Journal titled, "Post-transfusion non-A, non-B hepatitis in the Netherlands", the significance of NANBH and the need for a test for it was outlined.